Kitamura S, Tatsuta M, Yamamoto R, Iishi H, Kaji I, Kasugai H, Okuda S, Ishiguro S
CTR ADULT DIS,DEPT GASTROINTESTINAL ONCOL,HIGASHINARI KU,OSAKA 537,JAPAN. CTR ADULT DIS,DEPT PATHOL,HIGASHINARI KU,OSAKA 537,JAPAN. CTR ADULT DIS,DEPT GASTROENTEROL,HIGASHINARI KU,OSAKA 537,JAPAN.
Int J Oncol. 1993 Aug;3(2):245-51.
The relationships of cytological findings on periodic acid-Schiff (PAS) staining of fine-needle aspirates of hepatocellular carcinomas (HCC) with the length of survival of patients, their therapeutic response after transcatheter arterial embolization (TAE), and the tumor volume doubling time (TVDT) before chemoembolization were investigated in 74 patients with primary HCC. On the basis of cytologic findings on PAS-staining, HCC was classified into PAS-positive, mixed, and PAS-negative types. The two-year survival (70%) of patients with PAS-positive HCC was significantly longer than those of patients with the mixed or PAS-negative type of HCC. The TVDT of PAS-positive HCC was also significantly longer than that of the mixed type of HCC. These findings indicate that cytological findings on PAS-staining of HCC are useful in assessing the prognosis of patients with HCC.
对74例原发性肝细胞癌患者进行研究,以探讨肝细胞癌(HCC)细针穿刺抽吸物经高碘酸-希夫(PAS)染色后的细胞学检查结果与患者生存时间、经导管动脉栓塞术(TAE)后的治疗反应以及化疗栓塞术前肿瘤体积倍增时间(TVDT)之间的关系。根据PAS染色的细胞学检查结果,将HCC分为PAS阳性型、混合型和PAS阴性型。PAS阳性型HCC患者的两年生存率(70%)显著高于混合型或PAS阴性型HCC患者。PAS阳性型HCC的TVDT也显著长于混合型HCC。这些结果表明,HCC的PAS染色细胞学检查结果有助于评估HCC患者的预后。